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Abstract 
Lipid accumulation is a key characteristic of advancing atherosclerotic lesions. Here we 
analyzed the ultrastructure of the accumulated lipids in endarterectomized human carotid 
atherosclerotic plaques using three-dimensional (3D) electron microscopy, a method never 
used in this context before. 3D-electron microscopy revealed intracellular lipid droplets and 
extracellular lipoprotein particles. The majority of the particles were aggregated and some 
connected to needle-shaped or sheet-like cholesterol crystals. Proteomic analysis of isolated 
extracellular lipoprotein particles revealed that apolipoprotein B is their main protein 
component indicating their origin from low density lipoprotein, intermediate density 
lipoprotein, very low density lipoprotein, lipoprotein (a), or chylomicron remnants. The 
particles also contained small exchangeable apolipoproteins, complement components, and 
immunoglobulins. Lipidomic analysis revealed differences between plasma lipoproteins and 
the particles thereby indicating involvement of lipolytic enzymes in their generation. 
Incubation of human monocyte-derived macrophages with the isolated extracellular 
lipoprotein particles or with plasma lipoproteins that had been lipolytically modified in vitro 
induced intracellular lipid accumulation and triggered inflammasome activation in them. 
Taken together, extracellular lipids accumulate in human carotid plaques as distinct 3D-
structures that include aggregated and fused lipoprotein particles and cholesterol crystals. The 
particles originate from plasma lipoproteins, show signs of lipolytic modifications and 
associate with cholesterol crystals. By inducing intracellular cholesterol accumulation (ie, 
foam cell formation) and inflammasome activation, the extracellular lipoprotein particles may 
actively enhance atherogenesis. 
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Introduction  
Atherosclerosis underlies carotid artery disease, which is one of the leading causes of 
ischemic strokes.1 In carotid arteries, like in other atherosclerosis-susceptible arterial beds, 
circulating liver-derived apolipoprotein B (apoB)-100–containing and gut-derived apoB-48–
containing lipoprotein particles enter the arterial wall,2 and may so initiate and sustain the 
development of atherosclerotic lesions. The atherogenic lipoproteins capable of entering 
arterial intima, the site of atherogenesis, are very low density lipoprotein (VLDL) remnants, 
low density lipoprotein (LDL) particles, and chylomicron remnants.3,4 In the intima, the 
particles bind to extracellular matrix proteoglycans via apoB or apoE.5-7 
The retained lipoprotein particles are susceptible to a variety of modifications, such as 
proteolysis, lipolysis, and oxidation,8 and, indeed, lipoprotein particles isolated from 
atherosclerotic lesions show signs of these types of modifications.9-12 Intimal macrophages, 
mast cells, and smooth muscle cells secrete various proteolytic, lipolytic, and oxidizing 
enzymes, and biologically active agents, many of which have been shown to be able to attack 
lipoprotein particles. These include cathepsins,13-16 matrix metalloproteinases17, and mast cell 
chymase18,19, various forms of phospholipase A2 (PLA2), and secreted sphingomyelinase 
(SMase).20-24 Importantly, proteolyzed or oxidized LDL particles are more susceptible to 
lipolytic modifications,14,20,25 a finding that supports the concept of multiply-modified 
lipoprotein particles. 
Modification of LDL surface changes the conformation of apoB-100.26,27 Perturbations of the 
surface phospholipid monolayer also enable efficient hydrolysis of the cholesteryl esters (CE) 
and triacylglycerols (TAGs) in LDL core, thus causing transformation of LDL particles into 
liposomes and multilamellar vesicles.28 Indeed, the presence of cholesteryl esterase–modified 
LDL has been verified in atherosclerotic lesions.25 As hydrolysis of CEs leads to the 
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generation of unesterified cholesterol, the critical concentration of cholesterol may be 
surpassed, thus allowing nucleation of cholesterol crystals.29,30  
Surface changes may lead to aggregation of the particles.8 Aggregated and fused lipoprotein 
particles have a higher affinity for arterial proteoglycans than monomeric lipoproteins, 
promoting their retention within the extracellular matrix.31 In the intima, the modified and 
aggregated lipoprotein particles can also be taken up by macrophages or smooth muscle cells, 
which then gradually become foam cells.32,33 Uptake of modified LDL can also induce 
nucleation of cholesterol crystals in the lysosomes of the cells.34 Cholesterol crystals, whether 
taken up or generated within the lysosomes, have an ability to activate the NLRP3-
inflammasome,35-37 a complex that regulates the generation of active caspase-1, which, again, 
catalyzes the cleavage of pro–IL-1β and pro–IL-18 into their biologically active secretable 
forms. The expression of several key inflammasome components has been shown to be 
increased in atherosclerotic lesions.38 In addition to cholesterol crystals, also other lipids 
formed upon LDL modification can induce inflammatory activation of macrophages. Of 
those lipids, lysophospholipids, and, in presence of glucose, also unesterified fatty acids have 
been shown to induce IL-1β secretion by macrophages.39,40 
In this study, the ultrastructure of the lipoprotein particles accumulated in advanced human 
atherosclerotic lesions was first examined in situ. This was conducted by analyzing samples 
of endarterectomized carotid atherosclerotic plaques by three-dimensional electron 
microscopy (3D-EM), a method not previously used in this context. The extracellular 
lipoprotein particles present in the plaques were then isolated and molecularly characterized; 
they were found to be metabolically relevant lipoprotein-derived structures, which can induce 
not only lipid-accumulation but also inflammation in atherogenesis.   
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Materials and Methods 
Ethics statement 
The use of human material conforms to the principles outlined in the Declaration of Helsinki 
and the study protocol was approved by the local Medical Ethics Committee. All patients had 
signed an informed consent document. Human plasma and buffy coats were obtained from 
healthy blood donors (Finnish Red Cross Blood Service, Helsinki, Finland), who had signed 
an informed consent document. The plasma samples were by-products from the preparation 
of blood products for clinical use. The use of the samples was approved by the Finnish Red 
Cross Blood Service. 
Carotid artery samples 
Atherosclerotic plaques from human external or common carotid arteries were acquired from 
patients undergoing carotid endarterectomy operation in the Department of Vascular Surgery 
of the Helsinki University Hospital. Altogether 322 tissue pieces, one per plaque, from 279 
patients, were cut from the endarterectomized carotid plaques, and used in this study. Intimal 
pieces for immunohistochemistry (four plaques from four patients) or electron microscopy 
(six plaques from six patients, four of them same as for immunohistochemistry) were fixed 
and processed immediately after the excision. Pieces intended for lipoprotein particle 
isolation and consequent analyses were frozen in liquid nitrogen and stored at -80 °C until 
use.  
3D-electron microscopy 
The plaque pieces for 3D-EM were fixed with 2% formaldehyde, 2.5% glutaraldehyde, in 
0.1 M Na-cacodylate buffer (pH 7.4) supplemented with 2 mM CaCl2 for two to three h. The 
fixed samples were stored in 0.1 M Na-cacodylate-2 mM CaCl2 buffer containing 2% of 
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paraformaldehyde for stability and were further processed using a previously described 
protocol for enhanced contrast.41,42 Durcupan ACM resin (Merck Sigma-Aldrich Darmstadt, 
Germany) was mixed according to the manufacturer’s recommendations. After dehydration 
and infiltration, samples were embedded in silicone holders filled with 100% Durcupan and 
incubated for at least two h before polymerization at 60 °C. A pyramid of tissue was trimmed 
and mounted on a pin using conductive epoxy glue (CircuitWorks 2400 Kennesaw, GA) for 
serial block-face electron microscopy (SBEM). Finally, the sides of the pyramid were 
covered with silver paint (Agar Scientific Ltd. Stansted, UK) and the whole assembly was 
platinum-coated using Quorum Q150TS (Quorum Technologies, Laughton UK). SBEM 
datasets were acquired with a FEG-SEM Quanta 250 (FEI; Hillsboro, OR), using a 
backscattered electron detector (Gatan Inc. Pleasanton, CA) with 2.5-kV beam voltage, spot 
size 3 and pressure 0.2 Torr. The block faces were cut with 40 nm increments and imaged 
with XY resolution of 20 nm per pixel. 
For electron tomography (ET), semi-thick 250-nm-sections were cut from a trimmed pyramid 
using a Leica ultracut UCT ultramicrotome and 10-nm colloidal gold particles were placed on 
top/below the section to serve as fiducial markers for the alignment. The dual axis tilt series 
was recorded using Tecnai FEG 20 transmission electron microscope (FEI) operating at 200 
kV. Images were acquired using SerialEM software43 and a 4k × 4k Ultrascan 4000 CCD 
camera (Gatan) at nominal magnification 9,600 ×, providing a 2 × binned pixel size of 1.94 
nm. For tilt series, the specimens were tilted at one-degree intervals using a high tilt specimen 
holder (model 2020; E.A. Fischione Instruments Roskilde, Denmark) between ±62°. The Tilt 
series were aligned and reconstructed with IMOD software package44 and the tomographic 
reconstruction was analyzed, modelled, and visualized with MIB45 (Version 0.999) and 
Amira (FEI) (version 6.0.1) software.  
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Immunohistochemistry 
For immunohistochemistry, antigen was retrieved using Tris-EDTA-buffer (pH 9.0, 10 mM 
Tris, 1 mM EDTA, 0.05 % Tween-20) for 30 minutes in 95 °C water bath, after which the 
sections were allowed to cool down in the buffer. Paraffin-embedded sections of carotid 
atherosclerotic plaques were stained for ApoB-100 (a mouse monoclonal anti-apoB antibody 
LS-C35039, Lifespan Biosciences, Seattle, WA, 1:100 or a polyclonal apoB antibody raised 
in sheep (1.6 µg/mL of IgG in antiserum of bleed # 20, Sheep L3, THL, Dr M. Jauhiainen, 
National Institute for Health and Welfare, Finland 1:100)), apoE (Clone WU E-4, Cat, sc-
53570, Santa Cruz Biotechnology, USA 1:100), apoA-I (Clone 1C5, Cat. MON5030, 
Monosan, Netherlands 1:5000), and apoC-III (polyclonal rabbit anti-apoC-III, clone H-75, 
Cat. sc-50377, Santa Cruz Biotechnology, Dallas, TX, 1:100). The antibodies were detected 
using DAKO EnVision Kit (Mouse DAB Cat, K4007, DAKO A/S, Denmark), rabbit anti-
sheep IgG-HRP (Cat. sc-2770, Santa Cruz Biotechnology, USA, 1:200), or DAKO 
EnVision+ System HRP (DAB) Rabbit (Cat, K4010, DAKO A/S, Glostrup Denmark), 
respectively. 
Lipoprotein modification and generation of cholesterol crystals 
LDL (d = 1.019 to 1.050 g/mL) and VLDL (d < 1.006 g/mL) were isolated from plasma 
donated by healthy volunteers using sequential ultracentrifugation.46 The lipoproteins (1 
mg/mL) were modified first by PLA2 (30 U/mL, bee venom PLA2, (P9279, Sigma Aldrich)), 
SMase (1000 U/mL, from Bacillus cereus, (S9396, Sigma Aldrich)), α-chymotrypsin (400 
U/mL (C4129, Sigma Aldrich)), or 5 µM CuSO4 in PBS containing 2 mM CaCl2 and 2 mM 
MgCl2. After incubation for 18h at 37 °C, the reactions were stopped by addition of phenyl-
methyl sulfonyl fluoride at a final concentration of 0.02 mg/mL (α-chymotrypsin) or the 
addition of EDTA at a final concentration of 10 mM (PLA2, SMase, and oxidation). In some 
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cases the particles were further modified by human recombinant lysosomal acid lipase47 
(LAL) (6 U/µL) in 5 mM in MES - 150 mM NaCl in presence of 2 mmol/L Ca2+,100 µmol/L 
Zn2+, 2 mmol/L Mg2+, at pH 5.0 for 24 to 72 h.47 Formation of cholesterol crystals was 
visualized in light microscopy using a polarizing filter. The cholesterol crystals applied to the 
cells were generated as follows36: cholesterol was dissolved in 95% ethanol at a concentration 
of 12.5 mg/mL at 60 °C, filtered while warm and left to crystallize at 20 °C for four to seven 
days. Crystals were dried by filtering, ground with a mortar and a pestle in sterile 
surroundings and kept at -20 °C until used. Endotoxin activity was tested from plasma 
lipoproteins, isolated extracellular lipoprotein particles, and the dry crystals with endotoxin 
kit using a kinetic measuring method (Limulus Amebocyte Lysate Pyrogent Plus, (N294-03, 
Cambrex, Lonza group AG, Basel, Switzerland). 
Isolation and analysis of extracellular lipoprotein particles 
Plaque pieces were pooled into sets of 10 to 20, each piece from an individual plaque, sets 
weighing on average 2,500 mg. Extracellular lipoprotein particles were isolated as described 
previously.48 Briefly, the snap-frozen tissue was homogenized under liquid nitrogen and 
lipoprotein particles were extracted first with buffer containing 0.15 M NaCl and thereafter 
with buffer containing 1.5 M NaCl. The combined extracts were ultracentrifuged for 21 h in 
SW41Ti rotor (Beckman Coulter, Indianapolis, IN, 40 000 rpm, gmax = 288 000 x g) at a 
density of 1.063 g/mL after which the lipoprotein particles were collected from the top of the 
ultracentrifugation tube.  
The size distribution of the lipoprotein particles was analyzed using rate zonal 
ultracentrifugation as described previously.48 Oxidized epitopes were determined with 
chemiluminescece immunoassay48 using mouse monoclonal antibodies recognizing 
malondialdehyde- and malondialdehyde acetaldehyde epitopes. The sizes of the extracellular 
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particles were measured using dynamic light scattering (Zetasizer Nano, Malvern 
Instruments, Malvern Works, Malvern, UK). The cholesterol and triglyceride contents of the 
lipoprotein particles were measured by a fluorometric Amplex Red cholesterol assay Kit 
(Cat. A12216, Thermo Fisher Scientific, Waltham, MA) and Triglyceride quantification kit 
(Cat. K622-100, BioVision, Milpitas, CA), according to manufacturer’s instructions.  
Western blotting 
Isolated extracellular lipoprotein particles, VLDL, LDL, and homogenized plaque tissue 
(tissue remnants after isolation of the extracellular lipoprotein particles were homogenized in 
RIPA-buffer using PowerLyzer 24 Bench Top Bead-Based homogenizer using zirconium 
oxide beads (MO Bio Laboratories (Carlsbad, CA)) were run in 4% to 20% SDS-PAGE gel 
(165 V 50 min), and transferred onto PVDF (Immobilon Psq, MerckMillipore KGaA, 
Darmstadt Germany) membrane using wet blot with 20 % methanol in the transfer buffer 
(200 mA, 60 min). The antibodies used were a polyclonal antibody against apoB-100 (Dr M. 
Jauhiainen, National Institute for Health and Welfare, Finland) and a respective secondary 
antibody, rabbit anti-sheep IgG-HRP (Cat.-2770, Santa Cruz Biotechnology, USA 1:2000), a 
monoclonal antibody against apoE (Clone WU E-4, Cat. sc-53570, Santa Cruz), and a 
respective goat anti-mouse (DAKO Cat. P0447, polyclonal Goat-anti-mouse HRP), and a 
guinea pig anti-human polyclonal antibody GP29 against perilipin 1 (Progen Biotechink 
GmbH, Heidelberg, Germany 1:2000) and a respective secondary antibody, a HRP-
conjugated Rabbit anti-Guinea-pig, 1:10000, (Invitrogen, Camarillo, CA). 
Lipid mass spectrometry  
The lipids were extracted49 from native LDL and isolated extracellular lipoprotein particles 
and dried under N2 flow and dissolved in chloroform/methanol (1:2). The samples were 
spiked with a mixture of several quantitative standards, and just prior to the analysis 1% (v/v) 
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of NH3 was added to each sample to support ionization and prevent adduct formation. The 
mass spectra indicating all positive ions, all negative ions or precursors of the ion m/z 184 
(specific fragment for choline head group) were recorded by Agilent 6490 Triple Quad 
LC/MS with iFunnel technology (Agilent Technologies, CA). The data were further analyzed 
with MassHunter (Agilent Technologies) and LIMSA50 software (Version 1.0), the latter 
employing the standards and a lipid library.  
High-performance thin layer chromatography 
Neutral lipid and phospholipid contents were determined using high performance thin layer 
chromatography. Aliquots (50 µL) of each lipid sample (in chloroform/methanol 1:2) and 
standards for each lipid class were applied onto silica plates with CAMAG Automatic TLC 
Sampler 4 (CAMAG, Muttenz, Switzerland). Standard curves were prepared separately for 
each lipid class. The lipids of the applied samples were separated on the plates by using as 
eluent hexane/diethyl ether/acetic acid/water (26/6/0.4/0.1) for neutral lipids and 
chloroform/methanol/acetic acid/water (25/17.5/3.8/1.75) for phospholipids. The plates were 
developed by dipping them in 3% CuSO4·5H2O + 8% H3PO4 aqueous solution, and heating 
them on a hot plate until visible sample lines. The lipids were quantified by scanning the 
plates under ultraviolet (254 nm) light by CAMAG TLC Scanner 3 and integrating the peak 
areas by winCATS program (CAMAG Version 1.1.3.0). 
Circular dichroism 
Circular dichroism was used to analyze the protein conformation of the extracellular 
particles. Samples of native LDL or extracellular particles (50 µg/mL) were analyzed by 
circular dichroism as described previously26,51 using a JASCO J-715 spectropolarimeter 
(Japan Spectroscopic Co.; Tokyo, Japan). For each sample, five spectra were averaged, and 
blank measurements were subtracted.  
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Sample preparation and proteolytic digestion of proteins for MS analysis 
Ten microgram of total protein amounts from delipidated samples were digested, using 
modified FASP protocol.52 The proteins were reduced, iodoacetamide alkylated, and digested 
in 10 kDa cut off Amicon®-0.5 filter (Millipore, Ireland) with lysine-C endopeptidase 
(Wako, Richmond, VA) in a ratio of 1:50 w/w in 4M urea, 0.1M ammonium bicarbonate. The 
peptide digests were collected by centrifugation and the digestion was continued using 
trypsin in a ratio of 1:50 w/w in 50 mM ammonium bicarbonate at ambient temperature. The 
peptide digests were collected and combined. The peptides were cleaned using C18 -reverse 
phase ZipTipTM (Millipore), re-suspended in 1 % TFA and sonicated in water bath for one 
minute. 
Liquid chromatography-high definition mass spectrometry (LC-HDMSE) 
Three-hundred nanogram of digested proteins were injected for liquid chromatography-mass 
spectrometry (LC-MS) analysis. The peptides were separated by nanoAcquity UPLC system 
(Waters) equipped with a trapping column 5 µm Symmetry C18 180 µm × 20 mm C18 
reverse phase (Waters), followed by an analytical 1.7 µm, 75 µm × 250 mm BEH-130 C18 
reversed-phase column (Waters), in a single pump trapping mode. The injected sample 
analytes were trapped at a flow rate of 15 µL/min in 99.5% of solution A (0.1 % formic acid). 
After trapping, the peptides were separated with a linear gradient of 3% to 35% of solution B 
(0.1% formic acid/acetonitrile), for 30 min at a flow rate 0.3 µL/min and stable column 
temperature of 35 °C. The samples were run in ion mobility data-independent analysis mode 
(HDMSE), in a Synapt G2-S mass spectrometer (Waters), by alternating between low 
collision energy (6V) and high collision energy ramp in the transfer compartment (20 to 45 
V) and using 1 sec cycle time. The separated peptides were detected online with mass 
spectrometer, operated in positive, resolution mode in the range of m/z 50 to 2000 amu. 150 
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fmol/µL of human [Glu1]-fibrinopeptide B (Sigma Aldrich) in 50% acetonitrile/0.1% formic 
acid solution at a flow rate of 0.3 µL/min was used for a lock mass correction, applied every 
30 sec. 
Protein database search 
ProteinLynx Global Server software (PLGS V3.0) (Waters) was used for protein 
identification. MSE parameters were set as follows: low energy threshold of 135 counts, 
elevated energy threshold of 30 counts, and intensity threshold of precursor/fragment ion 
cluster 750 counts. Database searches were performed against Homo sapiens UniProtKB-
SwissProt, reviewed, database (release 2016_1, 42145 entries) with Ion Accounting 
algorithm and using the following parameters: peptide and fragment tolerance: automatic, 
maximum protein mass: 750 kDa, min fragment ions matches per protein ≥ 7, min fragment 
ions matches per peptide ≥ 3, min peptide matches per protein ≥ 1, primary digest reagent: 
trypsin, missed cleavages allowed: 2, fixed modification: carbamidomethylation C, variable 
modifications: deamidation of NQ amino acid residues, oxidation of Methionine (M) and 
false discovery rate (FDR) < 4%. 
Cell culture  
Human primary monocytes were isolated from buffy coats obtained from the Finnish Red 
Cross Blood Service, Helsinki, Finland, and differentiated into macrophages in the presence 
of 50 ng/mL of macrophage-colony stimulating factor (M-CSF), as described.36 The cells 
were used on day 7 of culture. Prior to activation, the cells were primed with 1 µg/mL LPS 
(Lipopolysaccharides from Escherichia coli 0111:B4, Sigma Aldrich) for four h. Human 
primary monocyte–derived macrophages were given native and modified LDL particles (0.3 
to 0.4 mg/mL of protein), in vitro prepared cholesterol crystals (1 mg/mL), and extracellular 
lipoprotein particles (0.3 mg/mL of protein) isolated from the atherosclerotic lesions. After an 
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overnight incubation, media was collected for IL-1β-ELISA-analysis. Accumulation of 
cholesteryl esters in the cells was evaluated by thin layer chromatography. For this purpose 
cellular lipids were extracted by incubating PBS-washed cells with hexane/isopropanol 
mixture (3:2). The protein concentrations of the same cells were determined by first 
disrupting the cells with 0.2 N NaOH, after which the protein concentration was determined 
using BCA protein Assay Reagent Kit (232225, Pierce Biotechnology, Rockford, IL) 
ELISA-assays 
IL-1β–levels from the cell culture media were measured with ELISA (Human IL-1β/IL-1F2 
DUOSET ELISA kit, Cat. DY201, R & D Systems Oxon, United Kingdom), according to the 
manufacturer’s instructions. ApoB-100 was assessed from the extracellular lipoprotein 
particles using Human Apolipoprotein B (specific for apoB-100, does not recognize apoB-48) 
ELISA development kit (Cat. 3715-1A-6), Mabtech, Nacka Strand, Sweden.  
Statistical analysis 
Statistical analyses were performed using ANOVA on ranks with pair-wise Wilcoxon signed 
ranks test or the nonparametric Kruskal-Wallis test, available in the software package SPSS 
statistics version 23 (IBM, Armonk, NY); P < 0.05 was considered statistically significant.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
Results  
Electron microscopic imaging of atherosclerotic lesions 
Pieces of plaques derived from six different endarterectomized carotid atherosclerotic plaques 
were fixed using a mixture of formaldehyde and glutaraldehyde for maximal preservation of 
morphology. The fixed samples were further contrasted with four heavy metal staining steps 
prior plastic embedding. In transmission electron microscopy (TEM), foam cells, 
extracellular lipoprotein particles, and cholesterol crystals were observed. Figure 1A shows 
an example of a foam cell surrounded by extracellular lipoprotein particles and cholesterol 
crystals (at higher magnification in Figure 1B). The diameters of the extracellular particles 
ranged from 50 to 400 nm, whereas intracellular lipid droplets were much larger, their 
diameters ranging to more than 2000 nm. Supplemental Figure S1 shows a partial cross-
section of an atherosclerotic lesion starting from endothelial cells and extending 420 µm in to 
the intima. The enlargements show a group of large cholesterol crystals in the deep intima 
(Supplemental Figure S1B), cholesterol crystals inside and next to foam cells (Supplemental 
figure S1C-D), and very small cholesterol crystals (<0.5 µm) among extracellular lipoprotein 
particles (Supplemental Figure S1E-F).  
A specimen of an atherosclerotic carotid plaque was selected for serial block-face scanning 
electron microscopy (SB-EM), in which 340 block-faces, each 40 nm apart, were sequentially 
cut and imaged. The resulting volume was aligned and segmented to generate a 3D model of 
organization of cholesterol crystals and foam cells (Supplemental video S1). A representative 
block-face image is shown in Figure 1C. The micrographs acquired by SB-EM revealed 
three-dimensional cholesterol crystals embedded in lipoprotein particle-containing 
extracellular matrix. The 3D model generated from SB-EM dataset is shown in Figure 1D 
and in Supplemental videos S1 and S2. The needle-like crystals appeared to grow out of 
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exceptionally large extracellular lipoprotein particles, and some crystals appeared as very 
large sheet-like structures (Figure 1D). One of the foam cells appeared to be in the process of 
engulfing two cholesterol crystal sheets (Figure 1D; Supplemental video S2). To obtain the 
3D organization of the extracellular lipoprotein particles at higher resolution, electron 
tomography of the same plaque specimen was also performed, which allowed various 
projection images of a semi-thick section to be collected and reconstructed into a 3D 
tomographic volume. Using this method, aggregated lipoprotein particles, some of which 
appeared to be fusing (Figures 1E and 1F, Supplemental video S3) were observed. The 
diameters of these extracellular particles ranged from 15 to 135 nm indicating that some of 
the particles are smaller than plasma LDL (20 to 25 nm), whereas some were much larger.  
Generation of cholesterol crystals in vitro 
Hydrolysis of LDL with the combination of SMase and cholesteryl esterase produces 
cholesterol crystals in vitro.30 This observation and our present electron microscopic 
demonstration of cholesterol crystals appearing to grow out from extracellular lipoprotein 
particles prompted us to test whether also other modifications of plasma LDL, such as 
lipolysis with PLA2, oxidation, or proteolysis in combination with cholesteryl ester 
hydrolysis would be able to induce the formation of cholesterol crystals. Cholesterol is 
known to crystallize when a critical concentration of unesterified cholesterol has been 
achieved.53 We hypothesized that cholesterol crystallization would occur when CEs in LDL 
core are hydrolyzed into UC. Since destabilization of LDL surface significantly improves CE 
hydrolysis,13 LDL particles were first treated with α-chymotrypsin, SMase, or PLA2, or 
oxidized with CuSO4 to destabilize particle surface, and thereafter the particles were treated 
with LAL to hydrolyze the CEs in the LDL core. Examination of the modified LDL particles 
under polarized light showed that each of these modifications and even treatment of LDL 
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with LAL without any prior modification was able to induce the formation of cholesterol 
crystals (Supplemental Figure S2). 
Characterization of the extracellular lipoprotein particles 
Immunohistochemistry of carotid artery plaques showed the presence of apoB, apoE, apoA-I, 
and apoC-III, reflecting entry LDL and other plasma lipoproteins into the plaques 
(Supplemental Figure S3). To gain information of the origins and effects of the lipoprotein-
derived lipid particles, extracellular particles from plaques were next isolated and analyzed 
using a method optimized for this purpose.48 Pieces of 10 to 20 individual plaques were 
pooled for each lipoprotein particle isolation. The isolated extracellular lipoprotein particles 
were found to contain apoB-100, as demonstrated when analyzing them by chemiluminescent 
immunoassay (Supplemental Figure S4A) or Western blotting (Supplemental Figure S4B). In 
addition, apoE was detected in the extracellular lipoprotein particles by Western blotting 
(Supplemental Figure S4B). A more detailed proteomic analysis of extracellular lipoprotein 
particles by mass spectrometry confirmed the presence of apoB-100 and apoE, and indicated 
also the presence of other apolipoproteins, such as apoA-I and apoC-III, as well as 
complement components C3 and C9 and immunoglobulins IgG, IgM, and IgA (Supplemental 
Table S1). Markers of intracellular lipid droplets, such as perilipin were not detected in the 
isolated particles, whereas in the homogenized tissue perilipin was abundant (Supplemental 
Figure S4C).  
The extracellular lipoprotein particles contained epitopes recognized by antibodies generated 
against malondialdehyde-LDL and malondialdehyde acetaldehyde-LDL, indicating their 
oxidative modification (Figure 2A). Circular dichroism analysis indicated that the 
conformation of the proteins in the isolated extracellular lipoprotein particles differed from 
that in LDL particles and that their α-helical content was much lower than that in plasma 
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LDL (Figure 2B). The extracellular lipoprotein preparations were found to contain 
cholesterol crystals (Fig. 2C). The proportions of PC and CE were lower and the proportion 
of free fatty acids higher than in LDL particles (Figure 2D) suggesting that the extracellular 
lipoproteins had undergone also lipolysis. The higher proportion of protein in the particles 
compared with plasma LDL points to the same, but may also be indicative of the extracellular 
lipoprotein particles containing several different proteins, as described above. The low PC 
content of the particles was reflected in a decrease in the proportion of a major PC species 
34:2 (Supplemental Figure S5A). Changes in the lysophosphatidylcholine and sphingomyelin 
species were more subtle (Supplemental Figure S4B and C, respectively). The CE 
composition of the extracellular lipoprotein particles differed from that of plasma LDL. Thus, 
although the proportion of CE 18:2, the most common CE in LDL, was dramatically lower in 
the extracellular lipoprotein particles, they had a high but varying proportion of CE 18:3 
(Supplemental Figure S6). 
Dynamic light scattering analysis revealed that the isolated extracellular lipoprotein particles 
were much larger (40 to 1000 nm) than plasma LDL (average diameter 24 nm) or VLDL 
(average diameter 58 nm) (Figure 3A). The extracellular lipoproteins had a wide size 
distribution also when analyzed using rate zonal ultracentrifugation (Figure 3B and 3C). 
Cholesterol was distributed among the small and large particles, whereas TG was found only 
in the largest particles (Figure 3B). ApoE and ApoA-I were found only in the small particles, 
and their molar concentrations were much lower than that of apoB-100. Immunoreactive 
apoB-100 was found mainly in the small particles. In this assay, an antibody against a C-
terminal epitope is used. As this epitope is not present in apoB-48, the finding suggests the 
larger particles may be derived from apoB-48-containing particles or that apoB-100 in the 
large particles had been partially lost or modified (Fig 3C).  
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Proinflammatory activity of isolated extracellular lipoprotein particles  
Cholesterol crystals are a known activator of the NLRP3 inflammasome, an inflammatory 
pathway that leads to activation of caspase-1 and to secretion of caspase 1–activated IL-1β 
and IL-18.35,36 To study whether the isolated extracellular lipoprotein particles are able to 
induce inflammasome activation, monocyte-derived macrophages were incubated with or 
without 1 µg/mL of LPS, after which the cells were further incubated in the presence of the 
lipoprotein particle preparations or, as a positive control, in vitro generated cholesterol 
crystals. In the primary human monocyte-derived macrophages, LPS induces transcription of 
NLRP3 and IL1B, and thereby serves as a necessary priming signal for inflammasome 
activation and IL-1β secretion.54 The lipoprotein particle preparations and cholesterol crystals 
induced secretion of IL-1β in LPS-primed, but not in non-primed human macrophages 
(Figure 4A). In the non-primed macrophages, the lipoprotein particle preparations, similar to 
in vitro–generated cholesterol crystals,36 did not induce significant expression of NLRP3 or 
TNFA, nor did they induce expression of MCP1 (not shown).  
To test whether modified lipoproteins were able to induce IL-1β secretion and activation of 
inflammasome complexes similar to the isolated lipoprotein particle preparations, LDL 
surface phospholipids and proteins were first modified using either proteolysis, lipolysis, or 
oxidation of the particles, after which the core CEs were hydrolyzed by LAL. All these 
modifications induced formation of cholesterol crystals (Supplemental Figure S2). LDL 
hydrolyzed with a combination of PLA2 and LAL induced a robust IL-1β secretion (Figure 
4B), but unexpectedly, neither oxidized LDL nor oxidized LDL treated with LAL was able to 
induce IL-1β secretion by the human macrophages. Similar to LDL modified with PLA2 and 
LAL, also VLDL modified by the same enzymes induced secretion of IL-1β (Figure 4C). 
Secretion of IL-1β could be inhibited by a caspase-1-inhibitor thereby confirming that it was 
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inflammasome-dependent (Figure 4D). Also, inhibition of uptake of the extracellular 
lipoprotein particles or modified LDL with cytochalasin D partly inhibited IL-1β secretion 
(Figure 4D). The isolated extracellular lipoproteins, VLDL (both native and lipolyzed with 
PLA2 and LAL), LDL lipolyzed with PLA2 and LAL, and cholesterol crystals, all were able 
to induce CE accumulation in the cells, but there were marked compositional differences 
between the differently treated cells (Figure 5). Thus, cholesterol crystals and modified LDL 
induced accumulation of CEs, whereas the extracellular lipoprotein particles and native and 
lipolyzed VLDL induced particularly the accumulation of TAGs. Cholesterol crystals 
induced also accumulation of UC.  
Discussion 
To understand the origin of lipid accumulating in atherosclerotic plaques and their 
pathophysiological significance in human atherogenesis, we assessed the ultrastructure, 
chemical composition, and proinflammatory potential of lipoprotein particles isolated from 
endarterectomized carotid artery plaques. We demonstrate that the extracellular lipoprotein 
particles are derived from modified apoB-containing plasma lipoproteins and when these 
particles were added to cultured human monocyte-derived macrophages, they triggered 
proinflammatory activation of macrophages and induced lipid accumulation in the cells in 
vitro. 3D-EM of the plaques revealed areas where the extracellularly located lipoprotein 
particles, foam cells, and cholesterol crystals were co-localized.  
ApoB-100 was found to be the main protein component of the isolated extracellular 
lipoprotein particles, indicating that the particles were derived from the atherogenic class of 
plasma lipoproteins containing this apolipoprotein. In addition, chylomicron remnants, 
another likely source of plasma-derived plaque lipids, also contribute to the accumulating 
extracellular lipids in the carotid plaques. Mass spectrometric analysis of the particle proteins 
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confirmed the presence of several small exchangeable apolipoproteins, including apoE, 
apoA-I, apoC-I, and C-III, which are known to be present in all major lipoprotein classes.55,56 
The extracellular lipoprotein particles contained also complement components, which have 
been detected in plasma HDL particles.57 Moreover, immunoglobulins were found to be 
associated with the extracellular lipoprotein particles, a finding suggesting local formation of 
immunocomplexes, such as have been reported for oxidized LDL in human atherosclerotic 
lesions.58 The isolated particles did not contain markers of intracellular lipid droplets, such as 
perilipin. The apolipoprotein composition of the extracellular lipoproteins suggests that they 
are derived from multiple classes of plasma lipoproteins from chylomicron remnants to HDL 
particles. As apoE is secreted by macrophages59, it is also possible that this protein as well as 
complement components and immunoglobulins are be incorporated into the extracellular 
lipoproteins in the tissue.  
Circular dichroism analysis indicated that the protein components of the isolated lipoprotein 
particles had largely lost their secondary structure. This may have resulted from degradation 
of the protein components or, also from lipolytic modifications since lipolytic modifications 
of plasma lipoproteins have been reported to compromise the conformation of their 
apolipoproteins.26,60 Indeed, when compared to native LDL particles, the lipid composition of 
the isolated lipoprotein particles suggested that they had been exposed to the action of both 
phospholipases and cholesteryl esterases. Their low CE and PC content, as well as decreased 
PC/SM ratio are also in accordance with previously published results.12,61,62 Compared to the 
PC species profile of LDL, the lipoprotein particles were enriched with oxidation-resistant 
saturated and monounsaturated species, and also with arachidonic acid–containing species 
with a proinflammatory potential (eg, PC 38:4, acyl pair 18:0/20:4n-6).  
The lipoprotein particle preparations were also found to contain cholesterol crystals. 
Importantly, hydrolysis of CEs in the core of plasma lipoprotein particles can induce 
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formation of cholesterol crystals, as previously shown by Guarino and co-workers by 
producing cholesterol crystals by hydrolysis of LDL with SMase and cholesteryl esterase.30 
Here, we show that modification of the surface of LDL particles by proteolysis, 
phospholipolysis, or oxidation facilitates effective CE hydrolysis leading to induction of 
cholesterol crystal formation. These modifications have also been shown to induce 
aggregation and fusion of plasma LDL particles,8 findings compatible with our present 
electron microscopic observations of aggregated and fused lipoprotein particles in carotid 
atherosclerotic plaques 
Various electron microscopic techniques (SEM and TEM) have been previously used to 
image foam cells and extracellular lipoprotein particles in atherosclerotic plaques derived 
from animals63-65 or humans.66-68 Interestingly, freeze-fracturing combined with SEM has 
provided images of the lipid particles and of their lamellar structure.65,69 In this study, we 
used two complementary EM techniques, electron tomography, which allowed us to detect 
individual lipoprotein particles even in their fusion process, and SB-EM, which allowed 
observation of cholesterol crystals, extracellular lipoprotein particles, and foam cells within 
an atherosclerotic plaque. These techniques made it possible to examine the 3D structure of 
the plaque microdomains and thus to uncover novel information of the positioning and nature 
of the extracellular lipoprotein particles and cholesterol crystals in the intima. Models 
generated from SB-EM dataset revealed sheet-like cholesterol crystals that were as large as 
the neighboring foam cells, as well as needle-like crystals that were connected to extracellular 
particles and seemingly growing out of them. Such large sheet-like crystals have not been 
observed in atherosclerotic plaques with any other EM-technique. The sheet-like crystals 
represent likely late stage forms of the cholesterol crystallization process, which, as shown in 
bile, evolve from needle-like structures. 70 
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Interestingly, in the model generated from the SB-EM dataset, one of the plaque foam cells 
appeared to be in the process of phagocytosing cholesterol crystals. Uptake of cholesterol 
crystals by cultured macrophages has been found to activate the NLRP3-inflammasome in 
them.35,36 Inflammasome activation is a two-step process, in which the first step, the priming, 
is induced, eg, by LPS71, and leads to induction of transcription of NLRP3, CASP1, and IL1B, 
ie, to the generation of the machinery required for secretion of mature IL-1β. A potential 
source of LPS in atherosclerotic lesions are oral pathogens.72 Other priming components 
include components of the extracellular matrix, such as biglycan, that can interact with Toll-
like receptors73. In the second step, assembly and activation of the inflammasome complex is 
triggered by inflammasome activators, such as cholesterol crystals. In this study, we show 
that the plaque-derived lipoprotein particles are able to trigger inflammasome activation in 
LPS-primed macrophages. Cytochalasin D induced a partial reduction in the secretion of IL-
1β, indicating that the process was at least partly dependent on the internalization of the 
lipoprotein particles. The lipoprotein particle preparations contained cholesterol crystals 
rendering it possible that the observed inflammasome activation in the cultured human 
macrophages was caused solely by them. However, of all types of LDL modifications that 
induced the formation of cholesterol crystals, only those involving hydrolysis of both PCs 
and CEs were able to trigger robust IL-1β secretion in cultured human macrophages. 
This study demonstrates that the aggregated and fused extracellular lipoprotein particles 
present in human atherosclerotic lesions are derived mainly from apoB-containing plasma 
lipoproteins and that they have undergone modifications able to induce lipoprotein 
aggregation as well as formation of cholesterol crystals (Figure 6). The extracellular 
lipoprotein particle preparations induced inflammasome activation, and, therefore, the 
particles can be considered active inflammatory contributors in atherogenesis. Considering 
that IL-1β, a product of inflammasome activation, is able to induce secretion of matrix 
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metalloproteinase-1, an enzyme with collagenase activity,74,75 lipoprotein particle–induced 
inflammasome activation may also lead to weakening and rupture of an atherosclerotic 
plaque, and so contribute to the development of atherothrombotic complications. Moreover, 
as inflammasome activation has been shown to induce cell death by apoptosis and 
pyroptosis,76 uptake of extracellular lipoprotein particles may also contribute to death of 
intimal cells, and, like cholesterol crystals, associate with plaque vulnerability.77 Thus, 
plasma lipoproteins retained and modified in the arterial intima can induce both lipid 
accumulation and inflammation, two key processes that are involved in the formation and 
progression of atherosclerosis. Finally, multidimensional imaging of the extracellular 
lipoprotein particles in their genuine environment, ie, in a human atherosclerotic plaque, 
allows us to better define the ultrastructural architecture of human atherosclerotic lesions, and 
so aids in understanding of the detailed structure-function relationships of the lipid 
components in atherogenesis. 
Limitations of the study 
The method used for isolation of the extracellular lipoprotein particles is a compromise in 
that the homogenization needs to be sensitive enough to avoid breaking of the foam cells with 
ensuing release of their intracellular lipid droplets or causing artificial aggregation of the 
extracellular particles; yet, the homogenization needs to be efficient enough to be able to 
liberate lipid particles as much as possible. As we did not observe markers of intracellular 
lipid droplets in the proteomic analysis of the isolated particles, the presence of at least 
sizeable amounts of lipid droplets of intracellular origin among extracellular particles seems 
highly unlikely. Intracellular lipid droplets would also have been detected by their large size 
in the dynamic light scattering analysis and the rate zonal ultracentrifugation.48 A D2O-based 
ultracentrifugation was chosen during the isolation procedure, which is known to minimize 
the loss of small exchangeable apolipoproteins during the ultracentrifugation step. 55 Also 
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apoB-100 immunoaffinity columns were not selected to avoid examining only 
apolipoprotein−pre-specified particles, eg, only apoB-100 –containing particles.  
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Figure legends 
Figure 1. Electron micrographs of an external carotid artery intima containing foam cells, 
extracellular lipoprotein particles, and cholesterol crystals. A, B: TEM-micrograph 
representative of TEM-micrographic analysis of three plaques shows extracellular lipoprotein 
particles (black arrows in B) and intracellular lipid droplets. B: An enlargement of the boxed 
area in A. Based on TEM analysis, one plaque was selected for block face-scanning electron 
microscopy (SB-EM). C: The lowest block face image of the SB-EM dataset. D: 3D-model 
of extracellular lipid droplets, cholesterol crystals, and foam cells generated from SB-EM 
images. Cholesterol crystals (yellow) seem to grow out from large lipid droplets (short black 
arrowheads and inset). Large sheet-like crystals (black arrows) can be two-dimensionally as 
large as foam cells. The plasma membranes of the foam cells are artificially colored in 
transparent blue or green, the nuclei in light blue, and the intracellular lipid droplets in 
vermilion or maroon. Two cholesterol crystals are surrounded by the right-hand foam cell 
(white arrow). E, F: 3D models generated from tomographic reconstruction of the plaque 
used for SB-EM depict extracellular lipoprotein particles in a process of fusion. The scale 
bars indicate 5 µm (A, C, D), 0.5 µm (B), and 0.1 µm (E, F). Foam cells in A, B, C, and D 
are marked with asterisks. 
Figure 2. Characterization of the extracellular lipoprotein particles. A: Binding of four 
different monoclonal antibodies generated against malonaldehyde-LDL or malondialdehyde-
acetaldehyde-LDL to a single extracellular lipoprotein particle preparation. Fish gelatin was 
used as a negative control. The results are expressed as relative light units measured in 100 
ms (RLU/100 ms). B: Circular dichroism analysis of LDL and extracellular lipoprotein 
particles. Representative spectrum of extracellular lipoprotein particles isolated from a pool 
of 10 pieces derived 10 individual plaques. Similar results were obtained with another 
preparation of extracellular lipoprotein particles prepared from a pool of 10 plaque pieces 
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derived from another 10 individual plaques. The samples were diluted to give a protein 
concentration of 50 µg/mL, and far-UV circular dichroism spectra were recorded using a 0.1 
cm quartz cuvette in the region of 190 to 250 nm. Solid line, LDL; dashed line, extracellular 
lipoproteins; dotted line, zero level in CD[mdeg]. C: The presence of cholesterol crystals in 
the extracellular lipoprotein particle preparations was analyzed under polarized light. D: 
Lipid contents of the LDL and extracellular lipoprotein particles were determined by thin 
layer chromatography and are shown as mass percentages of the total mass (lipids + protein). 
Average of three preparations are shown. PC=phosphatidylcholine, SM=sphingomyelin, 
LPC=lysophosphatidylcholine, CE=cholesteryl ester, UC=unesterified cholesterol, FA=fatty 
acid, TAG=triacylglycerol. 
Figure 3. Size and fractionation of extracellular lipoproteins. A: Sizes of LDL, VLDL, and 
extracellular lipoprotein particles were measured with dynamic light scattering. The data are 
representative of three individual preparations. The extracellular lipoproteins were 
fractionated based on particle size using rate zonal ultracentrifugation and the amounts of 
total cholesterol and triglycerides (B), and the amounts of apoB-100, apoA-I, and apoE in 
each fraction were determined (C). Three lipoprotein particle preparations, each from a pool 
of 10 to 20 pieces of individual plaques, were analyzed by rate zonal ultracentrifugation. The 
cholesterol and apoB-100 contents were analyzed in each of these preparations. 
Triglycerides, apoA-I, and apoE were analyzed from one preparation of 10 pooled plaques. 
Figure 4. Inflammasome activation in human monocyte–derived macrophages. A: 
Monocyte-derived macrophages were primed with or without LPS for 4 h, after which 
extracellular lipoprotein particles or in vitro–generated cholesterol crystals were incubated 
with the cells for 18 h. The concentration of IL-1β was measured in cell culture supernatants 
(n = 6). B: LDL was modified by oxidation, proteolysis, or phospholipolysis either alone or 
in combination with LAL-induced cholesteryl ester hydrolysis for 18 h. Native or modified 
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LDL (n = 6−12) was then incubated with LPS-primed or non-primed human monocyte–
derived macrophages for 18 h after which the concentration of IL-1β was determined in the 
supernatants. C: LPS-primed human monocyte–derived macrophages were incubated with 
VLDL or VLDL modified with PLA2 and LAL (n = 6−18) for 18 hours. After the incubation 
the concentrations of IL-1β were determined from the supernatants. D: LPS-primed human 
monocyte–derived macrophages were incubated with LDL, LDL modified with PLA2 and 
LAL, or with extracellular lipoprotein particles in the absence or presence of caspase-1 
inhibitor Z-YVAD or cytochalasin D (CD), an inhibitor of cytoskeletal movements (n=10 to 
12). *P < 0.05; **P < 0.005. Each data point is shown as a diamond and averages are shown 
as columns. CC = Cholesterol crystal, LP = Extracellular lipoprotein particles, Ox-LDL = 
Cu-oxidized LDL, a-CT = α-chymotrypsin –modified LDL, SMase = sphingomyelinase-
modified LDL, PLA2 = phospholipase A2-modified LDL, LAL = lysosomal acid lipase-
modified LDL  
Figure 5. Lipid accumulation in human monocyte–derived macrophages. LDL, VLDL, 
enzymatically modified LDL (LDL+PLA2+LAL), enzymatically modified VLDL 
(VLDL+PLA2+LAL), in vitro–generated cholesterol crystals (CC), and extracellular 
lipoproteins (LP) were applied to human primary monocyte–derived macrophages. After 
incubation for 18 h, the cellular lipid contents were analyzed by TLC (n = 3–9). *P < 0.05.CE 
= cholesteryl ester, TAG = triacylglycerol, UC = unesterified cholesterol. Averages of the 
individual data points are shown as columns. 
Figure 6. Proposed role of extracellular lipoprotein particles in atherogenesis. Extracellular 
lipoprotein particles are derived from plasma apoB-containing lipoproteins by modification 
and aggregation. Such modifications can also induce formation of cholesterol crystals. The 
extracellular lipoprotein particles together with cholesterol crystals induce extracellular lipid 
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accumulation and can be taken up by macrophages, in which, together with cholesterol 
crystals, they induce foam cell formation and inflammasome activation with ensuing IL-1β 
secretion.  
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SUPPLEMENTAL MATERIAL 
Supplemental Figure legends 
Supplemental Figure 1. Electron micrograph of a partial cross section of a common carotid artery. (A) 
Combined TEM micrographs show a 420 µm partial cross section of a common carotid artery. The lumen 
and endothelial surface appear at the bottom of the image. Above the endothelium, foam cells are seen, and 
above the layer of foam cells, large cholesterol crystals are present. Panels BE show enlargements of the 
boxed areas. (B) Large cholesterol crystals form massive clusters. (C, D) Small cholesterol crystals are found 
both inside and outside of the foam cells (circles in panel D) (E, F) Small cholesterol crystals among the 
extracellular lipoprotein particles (circles in panel F). Scale bars and magnification factors: A 20 µm, 200x; 
B, 5 µm, 1000x; C, 20 µm, 400x; D, 2 µm, 2500x; E, 5 µm, 1000x; F, 2 µm, 4000x. 
Supplemental Figure 2. Induction of cholesterol crystal formation via modification of LDL. LDL was 
modified by oxidation, proteolysis, or lipolysis to induce perturbations in the surface of the particles, after 
which the pre-modified particles were treated with lysosomal acid lipase (LAL) to induce cholesteryl ester 
hydrolysis. The samples were analyzed for the presence of cholesterol crystals by birefringence under 
polarized light. (A) LDL oxidized with CuSO4 and lipolyzed with LAL. (B) LDL modified with 
phospholipase A2 (PLA2) and LAL. (C) LDL modified with sphingomyelinase (SMase) and LAL. (D) LDL 
proteolyzed first with α-chymotrypsin (αCT) and then treated with LAL. (E) LDL lipolyzed with LAL. Scale 
bar 10 µm (AE).  
Supplemental Figure 3. Representative immunohistochemical stainings of apolipoproteins in human carotid 
atherosclerotic intima. The areas with black borders in Panels AI are shown enlarged in panels BJ, 
respectively. (A, B) Polyclonal anti-apoB-100 antibody; (C, D) monoclonal anti-apoB-100 antibody (E, F); 
monoclonal anti-ApoE antibody; (G, H) monoclonal anti-ApoA-I antibody, and (I, J) monoclonal anti-ApoC-
III antibody. Scale bars 200 µm (A, C, E, G, I) or 100 µm (B, D, F, H, J). 
Supplemental Figure 4. Analysis of apoB-100 and apoE contents of the particles. (A) Extracellular 
lipoprotein particles were isolated from human carotid arteries and then analyzed for the presence of apoB-
100 using a chemiluminescent assay. The results are expressed as relative light units measured in 100 ms 
(RLU/100 ms). (B) The isolated extracellular lipoprotein particles (total protein concentration 0.8 mg/ml and 
0.3 mg/ml in samples #1 and #2, respectively), VLDL, and LDL particles were analyzed by Western blot 
using a polyclonal anti-apoB-100 antibody and a polyclonal anti-apoE antibody. (C) Extracellular lipoprotein 
particles and homogenized solid tissue remnants were analyzed by Western blot using polyclonal anti-Plin1 
antibody. Lanes: 1, size standards; 2-4, solid fragments of three different isolations; 5. Isolated extracellular 
lipoproteins from a single isolation. Each isolation round contains tissue from 10–20 different carotid 
arteries. LP= Extracellular lipoprotein particles 
 Supplemental Figure 5. Mass spectrometric analysis of choline phospholipids in isolated extracellular 
lipoprotein particles and in LDL. Lipid species profiles of the extracellular lipoprotein particles from (n= 4 
pooled isolations, each pool containing extracellular lipoprotein particles from 10–20 plaques) and LDL 
(n=3) were analyzed with ESI-mass spectrometry as described in Methods. Each column represents a molar 
percentage of the lipid species indicated.  
Supplemental Figure 6. Mass spectrometric analysis of cholesteryl esters in isolated extracellular 
lipoprotein particles and in LDL. Analysis of cholesteryl ester species of extracellular lipoprotein particles 
from (n= 4 pooled isolations, each pool containing extracellular lipoprotein particles from 10–20 plaques) 
and LDL (n=3) by their fatty acid composition was performed by ESI-mass spectrometry, as described in the 
2 
 
Methods. Each column represents a molar percentage of an individual cholesteryl ester species from the sum 
of all cholesteryl ester species.  
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Supplemental Table legend: 
Supplemental Table 1. Protein mass spectrometry on the extracellular lipoprotein particles. Criteria to 
include proteins: protein sequence covered at least 10 %, 5 or more peptides recognized, isoforms with 
identical mass removed, and only proteins with GREEN auto curate were accepted. Proteins were ordered 
according to protein top3 Matched Peptide Intensity Sum. 
Supplemental Video legends: 
Supplemental video 1. Serial block faces (340 layers at 40 nm intervals) imaged generated from a carotid 
artery intima.  
Supplemental video 2. 3-D model of a carotid artery intima generated from a SB-EM dataset comprising 
340 block face images at 40 nm intervals. Two foam cells (plasma membranes) are modeled in transparent 
green and light blue, their nuclei in blue, and their cytoplasmic lipid droplets in vermilion and maroon. 
Cholesterol crystals and extracellular particles are shown in yellow. 
Supplemental video 3. Extracellular particles in a process of fusion modeled from a TEM tomogram of a 
carotid artery intima. The extracellular particles are modeled in yellow. Multilamellar phospholipid surface is 
modeled in dark yellow. 
 Supplemental Table 1. Protein mass spectrometry on the extracellular lipoprotein particles. Criteria to include proteins: protein sequence covered at least 10 
%, 5 or more peptides recognized, isoforms with identical mass removed, and only proteins with GREEN auto curate were accepted. Proteins were ordered 
according to protein top3 Matched Peptide Intensity Sum. The lipoporoteins found are marked with bold textype.  
 
 
 
Protein Entry 
Protein 
Accession 
(Swiss Prot) 
Protein Description 
Protein 
score 
Protein 
average 
Mass 
Protein 
matched 
Peptides 
Protein 
sequence 
Coverage 
(%) 
Protein 
top3 
Matched 
Peptide 
Intensity 
Sum 
Protei
n 
Auto 
Curat
e 
1 APOA1_HUMAN P02647 Apolipoprotein A-I OS=Homo sapiens GN=APOA1 
PE=1 SV=1 
75923 30778 25 59,9 2215587
0 
Green 
2 HBB_HUMAN P68871 Hemoglobin subunit beta OS=Homo sapiens GN=HBB 
PE=1 SV=2 
96003 16112 10 76,9 1971286
0 
Green 
3 ACTH_HUMAN P63267 Actin_ gamma-enteric smooth muscle OS=Homo sapiens 
GN=ACTG2 PE=1 SV=1 
41893 42276 25 55,1 1170881
0 
Green 
4 HBA_HUMAN P69905 Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 
PE=1 SV=2 
9476 15315 7 57,8 8356400 Green 
5 ACTB_HUMAN P60709 Actin_ cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 
SV=1 
25631 42079 25 58,7 8111540 Green 
6 APOB_HUMAN P04114 Apolipoprotein B-100 OS=Homo sapiens GN=APOB 
PE=1 SV=2 
22426 516974 245 49,3 7613403 Green 
7 APOE_HUMAN P02649 Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 
SV=1 
33076 36268 28 62,8 7285466 Green 
8 APOD_HUMAN P05090 Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 
SV=1 
8808 21561 6 24,9 4833133 Green 
9 IGHG1_HUMAN P01857 Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 
12182 36619 12 42,7 4587963 Green 
10 TAGL_HUMAN Q01995 Transgelin OS=Homo sapiens GN=TAGLN PE=1 SV=4 11417 22668 13 53,7 2257899 Green 
11 MYL6_HUMAN P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 
PE=1 SV=2 
24147 17101 14 72,2 2254040 Green 
12 APOC3_HUMAN P02656 Apolipoprotein C-III OS=Homo sapiens GN=APOC3 
PE=1 SV=1 
22119 10852 5 53,5 2111973 Green 
13 MYH11_HUMAN P35749 Myosin-11 OS=Homo sapiens GN=MYH11 PE=1 SV=3 11022 228195 73 40,0 2101943 Green 
14 VIME_HUMAN P08670 Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 7384 53709 25 47,2 1957304 Green 
15 MYH9_HUMAN P35579 Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 10865 227787 73 38,8 1762550 Green 
16 MYL9_HUMAN P24844 Myosin regulatory light polypeptide 9 OS=Homo sapiens 
GN=MYL9 PE=1 SV=4 
34644 19884 18 72,7 1475450 Green 
17 A1AT_HUMAN P01009 Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 
PE=1 SV=3 
11233 46908 17 46,4 1390492 Green 
18 IGHG2_HUMAN P01859 Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 
PE=1 SV=2 
3789 36528 6 19,0 1366743 Green 
19 MYH10_HUMAN P35580 Myosin-10 OS=Homo sapiens GN=MYH10 PE=1 SV=3 5865 229969 73 42,2 1334933 Green 
20 VTNC_HUMAN P04004 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 4901 55104 11 33,1 1275587 Green 
21 POTEE_HUMAN Q6S8J3 POTE ankyrin domain family member E OS=Homo sapiens 
GN=POTEE PE=1 SV=3 
11939 122936 19 23,3 1245045 Green 
22 CLUS_HUMAN P10909 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 8346 53065 12 24,9 1173977 Green 
23 ACTBM_HUMAN Q9BYX7 Putative beta-actin-like protein 3 OS=Homo sapiens 
GN=POTEKP PE=5 SV=1 
11040 42359 6 20,5 1156171 Green 
24 TPM2_HUMAN P07951-2 Isoform 2 of Tropomyosin beta chain OS=Homo sapiens 
GN=TPM2 
5643 33047 9 30,6 928862 Green 
25 K2C1_HUMAN P04264 Keratin_ type II cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 
4495 66210 21 31,2 925092 Green 
26 MFGM_HUMAN Q08431-2 Isoform 2 of Lactadherin OS=Homo sapiens GN=MFGE8 7472 35474 12 43,0 917399 Green 
27 IGHA1_HUMAN P01876 Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 
PE=1 SV=2 
3404 38510 5 16,4 901777 Green 
28 LAC2_HUMAN P0CG05 Ig lambda-2 chain C regions OS=Homo sapiens 
GN=IGLC2 PE=1 SV=1 
26144 11465 5 62,3 831052 Green 
29 GELS_HUMAN P06396-2 Isoform 2 of Gelsolin OS=Homo sapiens GN=GSN 3908 80926 13 26,4 823551 Green 
30 TRFE_HUMAN P02787 Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 2422 79345 18 26,7 742905 Green 
31 RAB1A_HUMAN P62820 Ras-related protein Rab-1A OS=Homo sapiens 
GN=RAB1A PE=1 SV=3 
43052 22906 12 74,6 678850 Green 
32 TPM4_HUMAN P67936 Tropomyosin alpha-4 chain OS=Homo sapiens GN=TPM4 
PE=1 SV=3 
1813 28636 8 27,8 644756 Green 
33 SAMP_HUMAN P02743 Serum amyloid P-component OS=Homo sapiens 
GN=APCS PE=1 SV=2 
6433 25501 9 29,6 640091 Green 
34 A2MG_HUMAN P01023 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 
SV=3 
1358 164717 19 19,5 491581 Green 
35 TPM1_HUMAN P09493 Tropomyosin alpha-1 chain OS=Homo sapiens GN=TPM1 
PE=1 SV=2 
1114 32766 7 16,6 490363 Green 
36 TBB5_HUMAN P07437 Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 
SV=2 
5096 50127 13 44,1 452320 Green 
37 FLNA_HUMAN P21333 Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 1329 283477 43 23,2 424363 Green 
38 FIBG_HUMAN P02679-2 Isoform Gamma-A of Fibrinogen gamma chain OS=Homo 
sapiens GN=FGG 
7576 50124 12 26,8 422607 Green 
39 HPT_HUMAN P00738 Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 690 45890 8 20,2 408679 Green 
40 IGHM_HUMAN P01871 Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 
SV=3 
3213 49991 10 24,1 401535 Green 
41 RB11B_HUMAN Q15907 Ras-related protein Rab-11B OS=Homo sapiens 
GN=RAB11B PE=1 SV=4 
4656 24603 7 53,2 390997 Green 
42 RAB7A_HUMAN P51149 Ras-related protein Rab-7a OS=Homo sapiens 
GN=RAB7A PE=1 SV=1 
4534 23775 7 42,5 357066 Green 
43 CO3_HUMAN P01024 Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 1012 188688 32 19,6 342297 Green 
44 ML12B_HUMAN O14950 Myosin regulatory light chain 12B OS=Homo sapiens 
GN=MYL12B PE=1 SV=2 
28306 19836 14 72,7 336412 Green 
45 GNAI2_HUMAN P04899 Guanine nucleotide-binding protein G(i) subunit alpha-2 
OS=Homo sapiens GN=GNAI2 PE=1 SV=3 
2058 41021 8 21,4 335244 Green 
46 FIBB_HUMAN P02675 Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 
SV=2 
2571 56613 10 31,2 329146 Green 
47 RL40_HUMAN P62987 Ubiquitin-60S ribosomal protein L40 OS=Homo sapiens 
GN=UBA52 PE=1 SV=2 
8111 15013 5 47,7 322508 Green 
48 ANXA2_HUMAN P07355 Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2 2001 38832 10 35,1 321505 Green 
49 AXA2L_HUMAN A6NMY6 Putative annexin A2-like protein OS=Homo sapiens 
GN=ANXA2P2 PE=5 SV=2 
1887 38830 8 28,6 321505 Green 
50 CAD13_HUMAN P55290 Cadherin-13 OS=Homo sapiens GN=CDH13 PE=1 SV=1 3228 78743 13 22,3 310060 Green 
51 CATD_HUMAN P07339 Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 1208 45066 9 20,9 306636 Green 
52 RAB14_HUMAN P61106 Ras-related protein Rab-14 OS=Homo sapiens GN=RAB14 
PE=1 SV=4 
2113 24125 7 34,4 296955 Green 
53 G3P_HUMAN P04406-2 Isoform 2 of Glyceraldehyde-3-phosphate dehydrogenase 
OS=Homo sapiens GN=GAPDH 
3589 31719 7 32,1 293891 Green 
54 RAB2A_HUMAN P61019 Ras-related protein Rab-2A OS=Homo sapiens 
GN=RAB2A PE=1 SV=1 
2006 23717 8 46,7 291363 Green 
55 CAH1_HUMAN P00915 Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 
SV=2 
1814 28927 5 29,1 279235 Green 
56 FIBA_HUMAN P02671 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 
SV=2 
400 95715 15 11,0 278846 Green 
57 HSPB1_HUMAN P04792 Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 
PE=1 SV=2 
1596 22840 5 29,3 272562 Green 
58 APOA4_HUMAN P06727 Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 
PE=1 SV=3 
695 45399 8 22,7 267588 Green 
59 RB11A_HUMAN P62491 Ras-related protein Rab-11A OS=Homo sapiens 
GN=RAB11A PE=1 SV=3 
3158 24508 6 40,3 257958 Green 
60 RAB1B_HUMAN Q9H0U4 Ras-related protein Rab-1B OS=Homo sapiens 
GN=RAB1B PE=1 SV=1 
40696 22342 9 61,7 256012 Green 
61 FINC_HUMAN P02751 Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 467 266218 29 11,1 255394 Green 
62 HBD_HUMAN P02042 Hemoglobin subunit delta OS=Homo sapiens GN=HBD 
PE=1 SV=2 
37253 16170 6 49,0 254513 Green 
63 ANXA1_HUMAN P04083 Annexin A1 OS=Homo sapiens GN=ANXA1 PE=1 SV=2 3373 38942 13 45,7 252360 Green 
64 RHG01_HUMAN Q07960 Rho GTPase-activating protein 1 OS=Homo sapiens 
GN=ARHGAP1 PE=1 SV=1 
2144 50493 7 25,5 245082 Green 
65 ACTN1_HUMAN P12814-2 Isoform 2 of Alpha-actinin-1 OS=Homo sapiens 
GN=ACTN1 
836 103280 18 33,0 234403 Green 
66 CO9_HUMAN P02748 Complement component C9 OS=Homo sapiens GN=C9 
PE=1 SV=2 
370 64656 10 20,0 233880 Green 
67 VINC_HUMAN P18206-2 Isoform 1 of Vinculin OS=Homo sapiens GN=VCL 2374 117293 17 22,0 223471 Green 
68 NIBAN_HUMAN Q9BZQ8 Protein Niban OS=Homo sapiens GN=FAM129A PE=1 
SV=1 
644 104104 11 14,7 211735 Green 
69 TBB3_HUMAN Q13509 Tubulin beta-3 chain OS=Homo sapiens GN=TUBB3 PE=1 
SV=2 
4046 50889 14 40,9 210320 Green 
70 PON1_HUMAN P27169 Serum paraoxonase/arylesterase 1 OS=Homo sapiens 
GN=PON1 PE=1 SV=3 
629 39902 6 21,1 202057 Green 
71 PDLI7_HUMAN Q9NR12 PDZ and LIM domain protein 7 OS=Homo sapiens 
GN=PDLIM7 PE=1 SV=1 
1058 50928 11 22,1 192795 Green 
72 RAB5B_HUMAN P61020 Ras-related protein Rab-5B OS=Homo sapiens 
GN=RAB5B PE=1 SV=1 
3515 23935 8 35,4 179196 Green 
73 TLN1_HUMAN Q9Y490 Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 502 271935 38 18,3 175358 Green 
74 ACTN4_HUMAN O43707 Alpha-actinin-4 OS=Homo sapiens GN=ACTN4 PE=1 
SV=2 
589 105310 24 22,2 173469 Green 
75 ENOA_HUMAN P06733 Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 783 47511 8 23,0 165945 Green 
76 RSU1_HUMAN Q15404 Ras suppressor protein 1 OS=Homo sapiens GN=RSU1 
PE=1 SV=3 
1377 31540 5 24,2 156746 Green 
77 RAB5C_HUMAN P51148 Ras-related protein Rab-5C OS=Homo sapiens 
GN=RAB5C PE=1 SV=2 
1917 23711 9 43,5 155486 Green 
78 CERU_HUMAN P00450 Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 503 123061 16 12,6 154660 Green 
79 PGS1_HUMAN P21810 Biglycan OS=Homo sapiens GN=BGN PE=1 SV=2 1067 42053 7 15,8 153733 Green 
80 PLTP_HUMAN P55058 Phospholipid transfer protein OS=Homo sapiens GN=PLTP 
PE=1 SV=1 
832 54968 11 18,1 146646 Green 
81 EHD2_HUMAN Q9NZN4 EH domain-containing protein 2 OS=Homo sapiens 
GN=EHD2 PE=1 SV=2 
1144 61333 8 19,9 145628 Green 
82 KPYM_HUMAN P14618-3 Isoform 3 of Pyruvate kinase PKM OS=Homo sapiens 
GN=PKM 
850 56900 7 15,5 136216 Green 
83 CNN1_HUMAN P51911 Calponin-1 OS=Homo sapiens GN=CNN1 PE=1 SV=2 739 33342 8 42,8 129525 Green 
84 PLSL_HUMAN P13796 Plastin-2 OS=Homo sapiens GN=LCP1 PE=1 SV=6 435 70859 9 13,6 124837 Green 
85 TAGL2_HUMAN P37802 Transgelin-2 OS=Homo sapiens GN=TAGLN2 PE=1 SV=3 1525 22563 5 33,7 118009 Green 
86 ANXA5_HUMAN P08758 Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 973 35994 9 34,7 116156 Green 
87 C4BPA_HUMAN P04003 C4b-binding protein alpha chain OS=Homo sapiens 
GN=C4BPA PE=1 SV=2 
494 69086 6 12,2 115477 Green 
88 RAB8B_HUMAN Q92930 Ras-related protein Rab-8B OS=Homo sapiens 
GN=RAB8B PE=1 SV=2 
3394 23755 10 40,6 102571 Green 
89 EFHD1_HUMAN Q9BUP0 EF-hand domain-containing protein D1 OS=Homo sapiens 
GN=EFHD1 PE=1 SV=1 
1481 27042 9 40,2 102035 Green 
90 TBB4A_HUMAN P04350 Tubulin beta-4A chain OS=Homo sapiens GN=TUBB4A 
PE=1 SV=2 
3229 50042 11 36,7 99380 Green 
91 COF1_HUMAN P23528 Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3 1596 18731 6 27,7 99303 Green 
92 ANXA6_HUMAN P08133 Annexin A6 OS=Homo sapiens GN=ANXA6 PE=1 SV=3 269 76216 12 20,8 78279 Green 
93 IGHG4_HUMAN P01861 Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 
PE=1 SV=1 
3876 36454 7 23,6 73337 Green 
94 ANXA4_HUMAN P09525 Annexin A4 OS=Homo sapiens GN=ANXA4 PE=1 SV=4 950 36111 6 13,8 68210 Green 
95 1433Z_HUMAN P63104 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ 
PE=1 SV=1 
1133 27916 5 31,0 65901 Green 
96 PRDX2_HUMAN P32119 Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 
SV=5 
389 22063 5 22,2 59102 Green 
97 THRB_HUMAN P00734 Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 210 71520 9 10,1 55305 Green 
98 1433E_HUMAN P62258 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE 
PE=1 SV=1 
934 29345 6 41,6 34207 Green 
99 TBB4B_HUMAN P68371 Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B 
PE=1 SV=1 
3653 50287 12 40,5 33745 Green 
100 TBB6_HUMAN Q9BUF5 Tubulin beta-6 chain OS=Homo sapiens GN=TUBB6 PE=1 
SV=1 
2806 50313 8 29,2 31486 Green 
101 RAB5A_HUMAN P20339-2 Isoform 2 of Ras-related protein Rab-5A OS=Homo 
sapiens GN=RAB5A 
1976 22349 9 55,7 29108 Green 
102 HBG1_HUMAN P69891 Hemoglobin subunit gamma-1 OS=Homo sapiens 
GN=HBG1 PE=1 SV=2 
8137 16198 5 32,7 27489 Green 
103 MYH14_HUMAN Q7Z406 Myosin-14 OS=Homo sapiens GN=MYH14 PE=1 SV=2 1697 228840 27 14,6 4463 Green 
 
